Medicared For All Logo

Jonathan Bridges in Rockford, Alabama

Home Alabama Rockford

Jonathan Bridges has Hematology/oncology as his primary medical specialty. Their primary office is: 9518 Us Hwy 231 in Rockford, Alabama. There are 4 additional office locations for Jonathan Bridges that can be viewed towards the end of their profile.

They're a part of the: The Sylacauga Health Care Authority medical group which has around 30 members. You can call their office at 256-377-4366 to schedule an appointment. They also accept the Medicare-approved amount as payment in full. They attended University Of South Carolina School Of Medicine and graduated in 2002 (around 22 years of experience). They are not listed as doing telehealth appointments, but this may have changed. It can't hurt to call and check. If anything it may encourage them to make them available if they are not currently.


Jonathan M Bridges Office Phone and Directions

Jonathan Bridges
The Sylacauga Health Care Authority
9518 Us Hwy 231
Rockford, Alabama 35136
256-377-4366


Patient Ratings
Please rate your experience with Jonathan Bridges below to help others make a more informed decision. Thanks!
Current Rating: Loading...

Phone: 256-377-4366


Enter a starting address:


Healthcare Info for Jonathan Bridges

Medical School: University Of South Carolina School Of Medicine
Graduation Year: 2002
The Primary Medical Specialty for Jonathan Bridges is listed as: Hematology/oncology
Approximate Years of Experience: 22
PAC (PECOS ID)#: 3678645553
NPI #: 1598979973
NPI Created On: 05/09/2007
NPI Last Updated Listed as: 02/10/2015
Primary Taxonomy Code: 207RH0003X
License Number:
26776
Listed Gender: Male

Insurance, Services, Charges


Forms of insurance accepted by include, but are not limited to:

  • Humana
  • Bright Health Insurance Company
  • Blue Cross Blue Shield
  • Medicare

They are listed as accepting new patients.

Languages spoken by staff include: English.


Services and Procedures include:

  1. Insertion of needle into vein for collection of blood sample
  2. Complete blood cell count (red cells, white blood cell, platelets), automated test
  3. Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour
  4. Infusion into a vein for therapy, prevention, or diagnosis
  5. Infusion into a vein for therapy prevention or diagnosis additional sequential infusion up to 1 hour
  6. Injection beneath the skin or into muscle for therapy, diagnosis, or prevention
  7. Injection of different drug or substance into a vein for therapy, diagnosis, or prevention
  8. Infusion of chemotherapy into a vein up to 1 hour
  9. New patient office or other outpatient visit, typically 60 minutes
  10. New patient office or other outpatient visit, typically 60 minutes
  11. Established patient office or other outpatient visit, typically 15 minutes
  12. Established patient office or other outpatient visit, typically 15 minutes
  13. Established patient office or other outpatient, visit typically 25 minutes
  14. Established patient office or other outpatient, visit typically 25 minutes
  15. Initial hospital inpatient care, typically 50 minutes per day
  16. Initial hospital inpatient care, typically 70 minutes per day
  17. Subsequent hospital inpatient care, typically 15 minutes per day
  18. Subsequent hospital inpatient care, typically 25 minutes per day
  19. Injection, dexamethasone sodium phosphate, 1 mg
  20. Injection, diphenhydramine hcl, up to 50 mg

They took part in Medicare's Electronic Health Record Incentive Program which was designed to help move people over to electronic records and improve the systems that were already in place.
They took part in the Medicare Physician Quality Reporting System (PQRS).

Open Payments Data. This can include items to test (Durable Medical Equipment (DME)), Biological, Drug Samples, etc. This data must be reported to CMS.


Payments Total: $5

Number of Payments:: 1

Form of Payment: In-kind items and services

Third party is a Charity:: No

Record ID:: 788461929

Being Disputed:: No

Product Related: Yes

Drug or Biological: Biological

Product Category #1: Oncology

Name of Drug #1: DARZALEX

Open Associated Drug #1: 57894-502-05

Drug or Biological: Biological

Product Category #2: Oncology

Name Of Drug #2:: IMBRUVICA

Associated Drug #2: 57962-140-09


Payments Total: $22

Number of Payments:: 1

Form of Payment: In-kind items and services

Third party is a Charity:: No

Record ID:: 788461925

Being Disputed:: No

Product Related: Yes

Drug or Biological: Drug

Product Category #1: Oncology

Name of Drug #1: ERLEADA

Open Associated Drug #1: 59676-600-12

Drug or Biological: Drug

Product Category #2: Oncology

Name Of Drug #2:: BALVERSA

Associated Drug #2: 59676-030-56


Payments Total: $18

Number of Payments:: 1

Form of Payment: In-kind items and services

Third party is a Charity:: No

Record ID:: 788461933

Being Disputed:: No

Product Related: Yes

Drug or Biological: Drug

Product Category #1: Oncology

Name of Drug #1: IMBRUVICA

Open Associated Drug #1: 57962-140-09

Drug or Biological: Drug

Product Category #2: Oncology

Name Of Drug #2:: DARZALEX

Associated Drug #2: 57894-502-05


Payments Total: $19

Number of Payments:: 1

Form of Payment: In-kind items and services

Third party is a Charity:: No

Record ID:: 788461937

Being Disputed:: No

Product Related: Yes

Drug or Biological: Biological

Product Category #1: Oncology

Name of Drug #1: DARZALEX

Open Associated Drug #1: 57894-502-05

Drug or Biological: Biological

Product Category #2: Oncology

Name Of Drug #2:: IMBRUVICA

Associated Drug #2: 57962-140-09


Payments Total: $19

Number of Payments:: 1

Form of Payment: In-kind items and services

Third party is a Charity:: No

Record ID:: 788461941

Being Disputed:: No

Product Related: Yes

Drug or Biological: Biological

Product Category #1: Oncology

Name of Drug #1: DARZALEX

Open Associated Drug #1: 57894-502-05

Drug or Biological: Biological

Product Category #2: Oncology

Name Of Drug #2:: IMBRUVICA

Associated Drug #2: 57962-140-09


Payments Total: $10

Number of Payments:: 1

Form of Payment: In-kind items and services

Third party is a Charity:: No

Record ID:: 788461945

Being Disputed:: No

Product Related: Yes

Drug or Biological: Biological

Product Category #1: Oncology

Name of Drug #1: DARZALEX

Open Associated Drug #1: 57894-502-05

Drug or Biological: Biological

Product Category #2: Oncology

Name Of Drug #2:: IMBRUVICA

Associated Drug #2: 57962-140-09


Payments Total: $16

Number of Payments:: 1

Form of Payment: In-kind items and services

Third party is a Charity:: No

Record ID:: 788461949

Being Disputed:: No

Product Related: Yes

Drug or Biological: Biological

Product Category #1: Oncology

Name of Drug #1: DARZALEX

Open Associated Drug #1: 57894-502-05

Drug or Biological: Biological

Product Category #2: Oncology

Name Of Drug #2:: IMBRUVICA

Associated Drug #2: 57962-140-09


Payments Total: $16

Number of Payments:: 1

Form of Payment: In-kind items and services

Third party is a Charity:: No

Record ID:: 788461953

Being Disputed:: No

Product Related: Yes

Drug or Biological: Biological

Product Category #1: Oncology

Name of Drug #1: DARZALEX

Open Associated Drug #1: 57894-502-05

Drug or Biological: Biological

Product Category #2: Oncology

Name Of Drug #2:: IMBRUVICA

Associated Drug #2: 57962-140-09


Payments Total: $5

Number of Payments:: 1

Form of Payment: In-kind items and services

Third party is a Charity:: No

Record ID:: 788461957

Being Disputed:: No

Product Related: Yes

Drug or Biological: Drug

Product Category #1: Oncology

Name of Drug #1: ERLEADA

Open Associated Drug #1: 59676-600-12

Drug or Biological: Drug

Product Category #2: Oncology

Name Of Drug #2:: BALVERSA

Associated Drug #2: 59676-030-56


Payments Total: $16

Number of Payments:: 1

Form of Payment: In-kind items and services

Third party is a Charity:: No

Record ID:: 788461961

Being Disputed:: No

Product Related: Yes

Drug or Biological: Biological

Product Category #1: Oncology

Name of Drug #1: DARZALEX

Open Associated Drug #1: 57894-502-05

Drug or Biological: Biological

Product Category #2: Oncology

Name Of Drug #2:: IMBRUVICA

Associated Drug #2: 57962-140-09


Additional Office Locations

1. The Sylacauga Health Care Authority
315 W Hickory St
Sylacauga, AL 35150
Group Members: 30

Phone: 256-377-4366

Enter a starting address:


2. The Sylacauga Health Care Authority
110 S Anniston Ave
Sylacauga, AL 35150
Group Members: 30

Phone: 256-377-4366

Enter a starting address:


3. Hematology And Oncology Associates Of Alabama, Llc
339 Walker Chapel Plaza
Birmingham, AL 35068
Suite 109
Group Members: 8

Phone: 256-377-4366

Enter a starting address:


4. Hematology And Oncology Associates Of Alabama, Llc
513 Brookwood Blvd
Birmingham, AL 35209
Suite 275
Group Members: 8

Phone: 256-377-4366

Enter a starting address:


Hematology/oncology Professionals in Rockford

9518 Us Hwy 231
Rockford, AL
The Sylacauga Health Care Authority

9518 Us Hwy 231
Rockford, AL
The Sylacauga Health Care Authority

9518 Us Hwy 231
Rockford, AL
The Sylacauga Health Care Authority

Providers in The Sylacauga Health Care Authority

1.Mohamed Aldaher

315 W Hickory St
Sylacauga Al 35150-2913
The Sylacauga Health Care Authority
Internal Medicine

2.Khaleel Ashraf Md

9518 Us Hwy 231
Rockford Al 35136-5214
The Sylacauga Health Care Authority
Hematology/oncology

3.Khaleel Ashraf Md

315 W Hickory St
Sylacauga Al 35150-2913
The Sylacauga Health Care Authority
Hematology/oncology

4.Kevin Bevis

315 W Hickory St
Sylacauga Al 35150-2913
The Sylacauga Health Care Authority
Anesthesiology

5.Tasia Bradford

209 W Spring St
Sylacauga Al 35150-2974
The Sylacauga Health Care Authority
Nurse Practitioner

6.Jonathan Bridges

9518 Us Hwy 231
Rockford Al 35136-5214
The Sylacauga Health Care Authority
Hematology/oncology

View all 30 members of The Sylacauga Health Care Authority medical group